Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PRPO logo PRPO
Upturn stock ratingUpturn stock rating
PRPO logo

Precipio Inc (PRPO)

Upturn stock ratingUpturn stock rating
$15.7
Last Close (24-hour delay)
Profit since last BUY119.58%
upturn advisory
Strong Buy
BUY since 38 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/10/2025: PRPO (3-star) is a STRONG-BUY. BUY since 38 days. Profits (119.58%). Updated daily EoD!

Upturn Star Rating

rating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $19

1 Year Target Price $19

Analysts Price Target For last 52 week
$19 Target price
52w Low $3.9
Current$15.7
52w High $16.89

Analysis of Past Performance

Type Stock
Historic Profit 87.7%
Avg. Invested days 39
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 4.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/10/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 24.49M USD
Price to earnings Ratio -
1Y Target Price 19
Price to earnings Ratio -
1Y Target Price 19
Volume (30-day avg) 1
Beta 1.25
52 Weeks Range 3.90 - 16.89
Updated Date 07/10/2025
52 Weeks Range 3.90 - 16.89
Updated Date 07/10/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.06

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -15.45%
Operating Margin (TTM) -17.43%

Management Effectiveness

Return on Assets (TTM) -10.9%
Return on Equity (TTM) -25.29%

Valuation

Trailing PE -
Forward PE 15.43
Enterprise Value 25710578
Price to Sales(TTM) 1.22
Enterprise Value 25710578
Price to Sales(TTM) 1.22
Enterprise Value to Revenue 1.28
Enterprise Value to EBITDA -1.15
Shares Outstanding 1512010
Shares Floating 1335212
Shares Outstanding 1512010
Shares Floating 1335212
Percent Insiders 13.98
Percent Institutions 7.46

ai summary icon Upturn AI SWOT

Precipio Inc

stock logo

Company Overview

overview logo History and Background

Precipio, Inc. was founded in 1997, initially focusing on developing innovative solutions for the diagnostics industry. Over time, it has evolved into a provider of diagnostic services and technologies, primarily in the field of oncology.

business area logo Core Business Areas

  • Diagnostic Services: Precipio offers a range of diagnostic services, including pathology testing and hematopathology testing. These services are used to diagnose and monitor various diseases, particularly cancers.
  • HemeScreen: HemeScreen is Precipio's core technology, a comprehensive hematopathology testing service for bone marrow samples.
  • IV Cell: IV Cell is Precipio's core technology that includes cell culture.

leadership logo Leadership and Structure

The CEO of Precipio is Ilan Danieli. The company has a board of directors and a management team responsible for overseeing its operations and strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • HemeScreen: HemeScreen is Precipio's core hematopathology testing service. It offers a comprehensive analysis of bone marrow samples. Precise market share data is difficult to obtain, but the hematology diagnostics market is competitive, with competitors including large reference labs like Quest Diagnostics (DGX) and LabCorp (LH), as well as specialized hematology labs and academic medical centers.
  • IV Cell: IV Cell is a solution for accelerating oncology drug and treatment development. It grows and maintains cell cultures to optimize drugs before testing on the human body. Market share information is hard to obtain. The market of cell culture and drug development is dominated by players like Thermo Fisher Scientific (TMO) and Danaher (DHR).

Market Dynamics

industry overview logo Industry Overview

The diagnostics industry is experiencing growth, driven by aging populations, increasing prevalence of chronic diseases, and advancements in diagnostic technologies. The oncology diagnostics segment is particularly important.

Positioning

Precipio focuses on niche markets within the diagnostics industry, particularly hematopathology and oncology. It aims to provide specialized testing services and technologies to healthcare providers and pharmaceutical companies.

Total Addressable Market (TAM)

The global hematology diagnostics market is estimated to be in the billions of dollars. Precipio, as a smaller player, is positioned to capture a share of this market through its specialized services and technologies. The total addressable market for oncology diagnostics is significantly larger.

Upturn SWOT Analysis

Strengths

  • Specialized expertise in hematopathology
  • Proprietary technologies like HemeScreen and IV Cell
  • Focus on niche markets
  • Established relationships with academic medical centers

Weaknesses

  • Limited financial resources compared to larger competitors
  • Small market share
  • Dependence on key technologies
  • History of operating losses

Opportunities

  • Expanding HemeScreen and IV Cell's applications
  • Partnerships with pharmaceutical companies
  • Acquisitions of complementary technologies
  • Growth in the oncology diagnostics market

Threats

  • Competition from larger diagnostic companies (DGX, LH, TMO, DHR)
  • Changes in reimbursement policies
  • Technological obsolescence
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • DGX
  • LH
  • TMO
  • DHR

Competitive Landscape

Precipio faces significant competition from larger, more established players in the diagnostics industry. Its competitive advantages lie in its specialized expertise and proprietary technologies. However, it needs to overcome its financial challenges to compete effectively.

Major Acquisitions

Failed to find a historical Acquisition by Precipio

  • Year: 0
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: Failed to find a historical Acquisition

Growth Trajectory and Initiatives

Historical Growth: Precipio's growth has been uneven, with periods of revenue growth and periods of decline. The company has struggled to achieve profitability.

Future Projections: To be completed with analyst report

Recent Initiatives: Recent initiatives include expanding the applications of HemeScreen and pursuing partnerships with pharmaceutical companies for IV Cell

Summary

Precipio is a small diagnostic company with specialized expertise in hematopathology. Its HemeScreen and IV Cell technologies offer potential for growth, but the company faces significant competition and financial challenges. The company needs to execute its growth strategy and achieve profitability to create long-term value for shareholders. It must look out for the larger players that could replicate its offerings at a faster scale.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • Public Filings
  • Industry Reports

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Precipio Inc

Exchange NASDAQ
Headquaters New Haven, CT, United States
IPO Launch date 2000-07-18
Founder, President, CEO & Director Mr. Ilan Danieli
Sector Healthcare
Industry Diagnostics & Research
Full time employees 54
Full time employees 54

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.